checkpoint inhibitor — grants

Sort

10,766 grants matching “checkpoint inhibitor”

T cell expressed miR-155 promotes antitumor immunity and immune checkpoint blockade responses in colon cancer through repression of Ship1

$46,792

William Weihao Tang · University Of Utah · F30 · FY2023 · CA

Investigating the Roles of Phospholipase A2s and Diacylglycerol Signaling in Ferroptosis

$46,776

Annie J Lin · Columbia University Health Sciences · F30 · FY2022 · CA

Characterizing the DPP8/9 Pyroptotic Checkpoint with Chemoproteomic Protease Substrate Profiling

$46,765

Andrew Griswold · Weill Medical Coll Of Cornell Univ · F30 · FY2019 · CA

Defining the Mechanism and Function of DNA Double Strand Break Induced Inhibition of V(D)J Recombination

$46,752

Rebecca Ann Glynn · University Of Pennsylvania · F31 · FY2022 · AI

Determining Dendritic Cell Responses to Vaccine-based Immunotherapy in PDAC at Single Cell Resolution.

$46,752

Dimitrios N Sidiropoulos · Johns Hopkins University · F31 · FY2022 · CA

Targeting Serine and Glycine Metabolic Vulnerabilities in Melanoma Brain Metastasis

$46,752

Victoria Margarita Osorio Vasquez · New York University School Of Medicine · F31 · FY2022 · CA

Development of a tumor-activated IL12 prodrug to treat solid tumors

$46,752

Benjamin Moon · Ut Southwestern Medical Center · F30 · FY2023 · CA

The Interplay Between PD-1 Blockade and T cell Development in the Context of Thymic Regeneration in Prostate Cancer

$46,752

Breanna Caruso · Oregon Health & Science University · F31 · FY2022 · CA

Metabolically improving the generation, function, and persistence of therapeutic T cells for the treatment of cancer

$46,752

Andrew Frisch · University Of Pittsburgh At Pittsburgh · F31 · FY2022 · CA

Characterization of a novel suppressor of oncogenic CARD11 signaling.

$46,752

Nicole Marie Carter · Johns Hopkins University · F31 · FY2022 · CA

Metabolic reprogramming and tumor progression in LKB1 deficient NSCLC

$46,752

Austin C Boese · Emory University · F99 · FY2022 · CA

DNA mechanotechnology to investigate the role of PD1 biophysics in T cell signaling

$46,752

Anna Kellner · Emory University · F31 · FY2022 · CA

Small-molecule Inhibition of Glycogen Synthase Kinase-3 Sensitizes Colorectal Cancer Cells and Stimulates Immune Cells to Bolster Immune Cell-mediated Tumor Cytotoxicity

$46,752

Kelsey Elizabeth Huntington · Brown University · F31 · FY2022 · CA

Effect of APOBEC3 on Bladder Cancer Biology and Response to Immunotherapy

$46,752

Andrew Truong · Univ Of North Carolina Chapel Hill · F31 · FY2022 · CA

Interrogating the role of mutant KRAS allelic imbalance and co-mutated genes in targeted therapy response of NSCLC

$46,752

Bianca Diaz · Weill Medical Coll Of Cornell Univ · F31 · FY2022 · CA

AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection

$46,632

Steven Duc Tran · Northwestern University At Chicago · F31 · FY2023 · LM

Chemoproteomic discovery of secreted microbial enzymes for engineered probiotics

$46,631

Natalie Falco · University Of California-Irvine · F31 · FY2025 · AI

Dissecting innate immune mechanisms of resistance to checkpoint blockade therapy in bladder cancer

$46,592

Michelle Alyssa Tran · Icahn School Of Medicine At Mount Sinai · F30 · FY2022 · CA

Dissecting the Gut Microbiota for Immune Checkpoint Blockade (ICB) - Resisting Microbes and Exploring the Generalizability of Microbiota-ICB Studies

$46,592

Joan Shang · Icahn School Of Medicine At Mount Sinai · F30 · FY2022 · CA

Tumor Intrinsic Regulation of Immune Evasion Pathways in Melanoma

$46,516

Sheera Rosenbaum · Thomas Jefferson University · F99 · FY2019 · CA

Identifying mechanisms of response and resistance to immunotherapies in lung cancer

$46,516

Camila Robles-Oteiza · Yale University · F99 · FY2019 · CA

T cell expressed miR-155 promotes antitumor immunity and immune checkpoint blockade responses in colon cancer through repression of Ship1

Investigating the Roles of Phospholipase A2s and Diacylglycerol Signaling in Ferroptosis

Characterizing the DPP8/9 Pyroptotic Checkpoint with Chemoproteomic Protease Substrate Profiling

Defining the Mechanism and Function of DNA Double Strand Break Induced Inhibition of V(D)J Recombination

Determining Dendritic Cell Responses to Vaccine-based Immunotherapy in PDAC at Single Cell Resolution.

Targeting Serine and Glycine Metabolic Vulnerabilities in Melanoma Brain Metastasis

Development of a tumor-activated IL12 prodrug to treat solid tumors

The Interplay Between PD-1 Blockade and T cell Development in the Context of Thymic Regeneration in Prostate Cancer

Metabolically improving the generation, function, and persistence of therapeutic T cells for the treatment of cancer

Characterization of a novel suppressor of oncogenic CARD11 signaling.

Metabolic reprogramming and tumor progression in LKB1 deficient NSCLC

DNA mechanotechnology to investigate the role of PD1 biophysics in T cell signaling

Small-molecule Inhibition of Glycogen Synthase Kinase-3 Sensitizes Colorectal Cancer Cells and Stimulates Immune Cells to Bolster Immune Cell-mediated Tumor Cytotoxicity

Effect of APOBEC3 on Bladder Cancer Biology and Response to Immunotherapy

Interrogating the role of mutant KRAS allelic imbalance and co-mutated genes in targeted therapy response of NSCLC

AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection

Chemoproteomic discovery of secreted microbial enzymes for engineered probiotics

Dissecting innate immune mechanisms of resistance to checkpoint blockade therapy in bladder cancer

Dissecting the Gut Microbiota for Immune Checkpoint Blockade (ICB) - Resisting Microbes and Exploring the Generalizability of Microbiota-ICB Studies

Tumor Intrinsic Regulation of Immune Evasion Pathways in Melanoma

Identifying mechanisms of response and resistance to immunotherapies in lung cancer

Genome Integrity Through the Cell Cycle in Homeostasis and Cancer

FoxM1 and Oncogenic Pathways in Hepatocellular Carcinoma

Colorado Head and Neck Cancer SPORE

Molecular Regulation of B cells and T cells in Human SLE